Abstract 248P
Background
Many patients concern the body imbalance after mastectomy and it is often cited as justification for immediate-breast reconstruction (IBR). However, few studies have investigated the impact of mastectomy or IBR on scoliosis, and analyzed only a small number of patients. We investigated whether mastectomy impacts spine alignment compared to IBR with a large cohort.
Methods
We retrospectively reviewed the patients who underwent breast cancer surgery between 2004 and 2018 at a single institution. Using the deep learning-based algorithm (DeepNoid Inc.), we collected Cobb's angle from chest posteroanterior x-rays at three time points: pre-operation, postoperative one-year, and five-years. Patients who underwent bilateral surgery, delayed-reconstruction, or LD-flap were excluded.
Results
Totally 6246 patients were included: 3442 (55.1%), 1911 (30.6%), and 893 (14.3%) patients underwent breast-conservation surgery (BCS), mastectomy without IBR, and IBR, respectively. At postoperative five-years, the mastectomy group showed the significantly greater change in Cobb's angle compared to both the BCS (p<0.001) and IBR (p=0.004) groups, while there was no significant difference between the BCS and IBR groups (p=0.347). After adjusting for other clinicopathologic variables, operation methods, adjuvant hormone treatments, and the direction of cancer remained significant factors affecting vertebral alignment. However, there was no relationship between the excised breast weights and Cobb's angle. Propensity score matching also showed that mastectomy group has greater change in angle compared to the other groups (vs. BCS, p=0.041; vs. IBR, p=0.047). Cobb’s angle was more evidence among patients under 50 years old (p=0.016) and who administered hormone treatment (p=0.009). Lastly, significantly more patients experienced lumbar pain after mastectomy (8.4%) than after BCS (6.7%) or IBR (4.1%) during the surveillance (p<0.001).
Conclusions
This is the largest study that showed the significant change in thoracic spine alignment after mastectomy compared to BCS and IBR. The results would provide the evidence on recommending breast reconstruction especially for young patients and educating post-mastectomy postural correction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Seoul National University Hospital.
Disclosure
H. Lee; W. Han: Financial Interests, Personal, Stocks or ownership, Not relevant to this study: DCGen. All other authors have declared no conflicts of interest.
Resources from the same session
1957P - Integrative proteomic profiling in high-grade serous ovarian carcinoma: Unraveling biomarkers and therapeutic targets
Presenter: Ido Wolf
Session: Poster session 13
1958P - Influence of androgen deprivation therapy (ADT) on epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) features in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: Poster session 13
1968P - Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)
Presenter: Jonathan Rosenberg
Session: Poster session 13
1969P - Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
Presenter: Rohit Jain
Session: Poster session 13
1972P - Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE
Presenter: Amanda Nizam
Session: Poster session 13
1973P - Urine-based molecular testing identifies FGFR alteration-positive patients for treatment with TAR-210
Presenter: Felix Guerrero-Ramos
Session: Poster session 13
1974P - A phase II trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder
Presenter: Guarionex DeCastro
Session: Poster session 13
1975P - Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100
Presenter: Petros Grivas
Session: Poster session 13